British Journal of Haematology · 1973 · 19 citations · 8 references
Life SciencesGeneticsHematologyClinical ImmunologyHemostasisImmunogeneticsAntibody CharacterizationAntibody ScreeningBlood Group SerologyImmunoglobulin FunctionCommon Genetic VariantsFactor Viiia ComplexGenetic Risk Variants
S ummary . With an immunosorbent technique, we have found multiple genetic variants of haemophilia B. In one variant there is no detectable material that cross‐reacts with a human anti‐factor‐IX antibody. This variant is defined as negative for cross‐reacting material (CRM − ). There is also a CRM + variant in which the factor‐IX deficient plasma has the capacity to neutralize as much antibody as does normal plasma. There is an intermediate variety that neutralizes the specific antibody to a degree which is proportional to the factor‐IX clotting activity. This last group has been designated as having reduced cross‐reacting material (CRM R ). The CRM R group is probably heterogeneous, and it is likely that many genetic variants of haemophilia B exist.
8
HÆMOPHILIA BM: A NEW TYPE OF FACTOR-IX DEFICIENCY
Cecil Hougie, J.J. Twomey · The Lancet · 1967 · 109 citations
Medicine, Hematology, Pathology +11
Another Genetic Variant of Haemophilia B: Haemophilia B Leyden
J.J. Veltkamp, Jan F. Meilof, H. G. Remmelts et al. · Scandinavian Journal of Haematology · 1970 · 68 citations